Regulatory & Reimbursement
FDA Output, August 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in August 2026. Updated August 31.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Business Strategies
The NASS Innovation Summit: Enthusiasm for Spine Entrepreneurship in a Tough Market
At a NASS Summit on Spine Innovation, battle-hardened entrepreneurs, surgeons, investors, and healthcare system executives discussed lessons learned and takeaways for building companies in a financially constrained environment.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Pathways' Pick of the Week: FDA Floats GenAI Plan
FDA proposes a “competency” framework for regulating generative AI; Excerpted from Pathways Picks August 19: FDA GenAI Plan, Commish Nom, Global Picks, and More.